The bacterial lysate Lantigen B reduces the number of acute episodes in patients with recurrent infections of the respiratory tract: The results of a double blind, placebo controlled, multicenter clinical trial

Highlights • Old trials on LantigenB (LB) showed its effect on recurrent respiratory infections. • These studies were performed using non-updated clinical and statistical methods. • Here we show that LB reduces the number of infections in a phase IV clinical study. • LB represents a real first-line...

Full description

Saved in:
Bibliographic Details
Published in:Immunology letters 2014-12, Vol.162 (2), p.185-193
Main Authors: Braido, Fulvio, Melioli, Giovanni, Candoli, Piero, Cavalot, Andrea, Di Gioacchino, Mario, Ferrero, Vittorio, Incorvaia, Cristoforo, Mereu, Carlo, Ridolo, Erminia, Rolla, Giovanni, Rossi, Oliviero, Savi, Eleonora, Tubino, Libero, Reggiardo, Giorgio, Baiardini, Ilaria, di Marco, Eddi, Rinaldi, Gilberto, Canonica, Giorgio Walter, Accorsi, Carlo, Bossilino, Claudia, Bonzano, Laura, DiLizia, Michela, Fedrighini, Barbara, Garelli, Valentina, Gerace, Vincenzo, Maniscalco, Sara, Massaro, Ilaria, Messi, Alessandro, Milanese, Manlio, Peveri, Silvia, Penno, Arminio, Pizzimenti, Stefano, Pozzo, Tiziana, Raie, Alberto, Regina, Sergio, Sclifò, Francesca
Format: Article
Language:English
Subjects:
Acute Disease
Adolescent
Adult
Aged
Allergy
Allergy and Immunology
Antigens, Bacterial - administration & dosage
Asthma - drug therapy
Bacteria
Bacterial lysates
Double-Blind Method
Female
Follow-Up Studies
History, Ancient
Humans
Immune-stimulant drugs
Longitudinal Studies
Male
Middle Aged
Prophylactic treatment
Prospective Studies
Recurrent respiratory tract infections
Respiratory Tract Infections - drug therapy
Severity of Illness Index
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Old trials on LantigenB (LB) showed its effect on recurrent respiratory infections. • These studies were performed using non-updated clinical and statistical methods. • Here we show that LB reduces the number of infections in a phase IV clinical study. • LB represents a real first-line prophylaxis of recurrent respiratory infections.
ISSN:0165-2478
1879-0542
DOI:10.1016/j.imlet.2014.10.026